AKRO vs. ALBO, ENTA, CBAY, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Albireo Pharma (ALBO), Enanta Pharmaceuticals (ENTA), CymaBay Therapeutics (CBAY), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Akero Therapeutics (NASDAQ:AKRO) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
Albireo Pharma received 199 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 61.49% of users gave Akero Therapeutics an outperform vote while only 56.65% of users gave Albireo Pharma an outperform vote.
Akero Therapeutics has a net margin of 0.00% compared to Albireo Pharma's net margin of -228.51%. Akero Therapeutics' return on equity of -27.72% beat Albireo Pharma's return on equity.
Akero Therapeutics currently has a consensus price target of $41.13, suggesting a potential upside of 118.52%. Given Akero Therapeutics' higher possible upside, research analysts plainly believe Akero Therapeutics is more favorable than Albireo Pharma.
In the previous week, Akero Therapeutics had 11 more articles in the media than Albireo Pharma. MarketBeat recorded 11 mentions for Akero Therapeutics and 0 mentions for Albireo Pharma. Akero Therapeutics' average media sentiment score of 0.36 beat Albireo Pharma's score of 0.20 indicating that Akero Therapeutics is being referred to more favorably in the media.
Albireo Pharma has higher revenue and earnings than Akero Therapeutics. Albireo Pharma is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.
94.3% of Albireo Pharma shares are held by institutional investors. 7.9% of Akero Therapeutics shares are held by company insiders. Comparatively, 6.9% of Albireo Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Akero Therapeutics beats Albireo Pharma on 11 of the 16 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Akero Therapeutics Competitors List
Related Companies and Tools